Juan Jose Serrano
Juan Jose Serrano is Business Development Manager at Ardena. He brings experience in international business development, market analysis, and strategic account growth across the pharmaceutical and life sciences sectors.
Before joining Ardena, Juan Jose held international commercial and trade advisory roles across Europe and Australia, building expertise in global business development and commercial strategy. Over the past four years at Ardena, he has supported global business development activities across multiple regions and service areas, helping identify collaboration opportunities between biotech and pharmaceutical companies and Ardena’s integrated CDMO and CRO platform.
Juan Jose obtained his MBA and brings a strong international and client-focused perspective to strategic partnership development within the pharmaceutical industry.
Ben Vermeulen
Ben Vermeulen, PhD, is Business Development Director at Ardena. He brings a combination of scientific expertise and commercial experience, supporting biotech and pharmaceutical companies across drug development and CMC programs.
Ben joined Ardena in 2016 as part of the Project Management Office, where he guided clients through formulation development, GMP manufacturing, analytical development and validation, and clinical supply activities. He later transitioned into business development and technical CMC sales roles, supporting clients by bridging scientific and strategic aspects of pharmaceutical development. In parallel, he also served as Safety Coordinator, overseeing API safety-related activities at Ardena. His expertise spans immunobiology, clinical development, CMC, safety, highly potent APIs (HPAPIs), and nanomedicine.
Ben obtained his degree in Bio-engineering, specializing in Cell and Gene Biotechnology, and earned his PhD in Virology and Immunobiology from Ghent University. He began his career as a technology developer at a Belgian-Australian biotech start-up before moving into the investment sector, where he evaluated oncology therapeutics for a private investor.
